Cited by 85Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year

Open access
Knopman, D. S., Jack, C. R., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L. +1 more·2009·Neurology

Abstract

BACKGROUND: Measurement of volumetric changes with MR might be a useful surrogate endpoint for clinical trials in frontotemporal lobar degeneration (FTLD). Because there is only limited longitudinal imaging data currently available, we measured the rate of change over 1 year of whole brain volume (WBV) and ventricular volume (VV) in patients with FTLD. METHODS: Subjects with an FTLD cognitive syndrome were recruited from five centers using standard clinical diagnostic criteria for behavioral variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), semantic dementia (SMD), and progressive logopenic aphasia. Structural brain imaging, using three-dimensional T1-weighted sequences at 1.5 teslas, and cognitive, behavioral, and functional assessments were performed at baseline and approximately 1 year later. The boundary shift integral algorithm was used to determine change in WBV and VV. RESULTS: There were 76 patients (mean age 64 years; 41 men and 35 women) who had usable baseline and annual scans. The group-wise annualized change was -1.62% (SD 1.03, range +0.69 to -3.6) for WBV and 11.6% (SD 5.9, range -1.3 to 23.9) for VV. Rates of change were similar among bvFTD, PNFA, and SMD groups. Longitudinal changes in WBV and VV were correlated with decline on clinical global and cognitive measures. CONCLUSIONS: Multicenter, serial measurements of whole brain volume (WBV) and ventricular volume (VV) from magnetic resonance scans were feasible in patients with frontotemporal lobar degeneration (FTLD). Using WBV or VV as outcome measures would require recruiting (at 80% power) 139 or 55 subjects per group to detect a small (25%) or medium-sized (40%) effect in a randomized, placebo-controlled trial of a putative agent for FTLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181a71236

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Gunter JL, Shiung MM, Manduca A, Jack CR Jr. Meth- odological considerations for measuring rates of brain atro- phy. JMRI 2003;18:16-24.
  2. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Pat- terns of brain atrophy in frontotemporal dementia and se- mantic dementia. Neurology 2002;58:198-208.

Cited by

Sorted by citations

Authors
Knopman, D. S., Jack, C. R., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. D.
Affiliations
  • Mayo Clinic (US)
  • From the Mayo Clinic (D.S.K., C.R.J., B.F.B.), Rochester, MN; University of California (J.H.K.), San Francisco, CA; Mayo Clinic (R.J.C.), Scottsdale, AZ; Mayo Clinic (N.R.G.-R.), Jacksonville, FL; University of California (M.F.M.), Los Angeles, CA; University of California (B.L.M.), San Francisco, CA; and National Alzheimer's Coordinating Center (N.D.M.), Seattle, WA.
Venue
Neurology
Published
2009-05-26
Volume
72
Issue
21
Pages
1843-1849
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2061821269
Cited by
85
References
27
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 7 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 7 · 2012: 9
FWCI
5.55
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • National Institutes of Health (AG016976, AG023501, AG11378, U01 AG24904, AG19610, R01 AG11378, AG19724)
  • University of California, San Francisco
  • Pfizer Pharmaceuticals
  • National Institute on Aging (R01AG11378, AG 016976, AG-016570, P30-AG-19610, P50‐AG16574, U01AG06786, AG 16574, U01AG016976, AG-19610, P50AG016570, U01AG006786, U01AG24904, AG-19724, R01AG011378, AG-11378, AG023501, P30AG019610, R01AG023195, P01-AG19724, P01AG019724, P50AG023501, P50AG016574)
  • National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
frontotemporal lobar degeneration, total brain volume, ventricular volume, volume change, surrogate endpoints, behavioral variant frontotemporal dementia, progressive nonfluent aphasia, semantic dementia, longitudinal MRI, clinical trial design, cognitive decline
MeSH terms
Aged, Algorithms, Aphasia, Brain, Cerebral Ventricles, Clinical Trials as Topic, Dementia, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Severity of Illness Index, Linear Models, Aphasia, Primary Progressive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review